drugset / Trial / NCT06567600
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
Phase 2
Not yet recruiting
43 enrolled
Third Affiliated Hospital, Sun Yat-Sen University
Second Affiliated Hospital of Guangzhou Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
In this phase 2 study, researchers aimed to evaluate the efficacy and safety of low-dose gemcitabine and cisplatin chemotherapy and the immune checkpoint inhibitor PD-1/PD-L1 antibody in patients with advanced and unresectable intrahepatic cholangiocarcinoma.
Timeline
- Start
- 2024-09-01
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 12.5 mg/m2 | — |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Gemcitabine | Small molecule | 500 mg/m2 | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |